Speaker Profile
Ph.D., CEO & Co-Founder, 10x Genomics
Biography
Serge Saxonov is the co-founder and CEO of 10x Genomics, a leader in singlecell and spatial biology. 10xs mission is to accelerate the mastery ofbiology to advance human health. Under Serges leadership, 10x hasdelivered groundbreaking products that have transformed how researchersexplore biology. These tools and technologies have been cited in more than10,000 high-impact publications and have enabled discoveries across nearlyevery area of life sciences.As a scientist, inventor and entrepreneur, Serge guided 10x from anearly-stage startup through one of the fastest revenue ramps in theindustrys history to its public debut on Nasdaq (TXG), and has since ledthe companys continued growth and innovation. Before 10x, he was part ofthe founding team at 23andme, where he pioneered the companys coretechnology and product concepts, and later served as Vice President ofApplications at QuantaLife, which was acquired by Bio-Rad.Serges leadership and entrepreneurship have been recognized by GoldmanSachs, which named him one of its 100 Most Intriguing Entrepreneurs in2016, and by the San Francisco Business Times, which honored him as one ofthe Bay Areas Most Admired CEOs in 2021. He earned his A.B. in AppliedMathematics from Harvard College and his Ph.D. in Biomedical Informaticsfrom Stanford University.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: Erin Harris Cell & Gene
• David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
PMWC Award Ceremony
• Michel Sadelain, Columbia University
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
